How long can you delay the start of radiation in a patient who has received adjuvant chemotherapy after lumpectomy/mastectomy?
Question Created by Wainwright A. Jaggernauth
Related Questions
Abram Recht
Beth Israel Deaconess Medical Center
Endocrine therapy can be given simultaneously with RT without increasing toxicity or decreasing effectiveness, as shown in a randomized French-Swiss trial (Azria et al., PMID 20138810). Toxicities from chemotherapy may be greater and its effectiveness reduced (at least for high-risk patients) when given after RT instead of before (Recht et al., PMID 8614420; Bellon et al., PMID 15774786). Hence, I would give this patient endocrine therapy simultaneously with RT and chemotherapy before RT if she ...
(more)
Abram Recht
Beth Israel Deaconess Medical Center
Many studies have shown the true-positive rate of distant metastases on pretreatment imaging to be a few percent (at most) for patients with Clinical Anatomic Stage I-II cancers. The false-positive rate is much higher. Hence, such imaging should only be used when patients have suspicious symptoms or signs on examination.Current consensus guidelines recommend such staging for patients with Clinical or Pathologic Anatomic Stage III cancers or recurrent cancers. I also feel it's reasonable for sele...
(more)
Sushil Beriwal
Varian Medical Systems/Allegheny health network
For now, I have been only omitting/discussing omission if both, clinical path and molecular test are concordant.
(more)
Sushil Beriwal
Varian Medical Systems/Allegheny health network
We don’t perform mammograms routinely for this subset unless clinically indicated.
(more)
Naamit Gerber
New York University School of Medicine
With the publication of KEYNOTE-522 (Schmid et al., PMID 32101663), we are seeing this scenario much more frequently as patients continue the pembrolizumab in the adjuvant setting.A post-hoc analysis of the timing of radiation in the KEYNOTE-522 trial was presented in abstract form at SABCS 2022, (PD3-01, McArthur et al.) They divided patients between those patients who recieved RT concurrently (n=144) with pembo vs. sequentially (n=280) to pembro. The EFS benefit for pembro vs. placebo was ther...
(more)
Abram Recht
Beth Israel Deaconess Medical Center
Results of the NSABP B-51 trial were presented at the 2023 San Antonio Breast Cancer Symposium (Mamounas et al., abstract GS-02-07). This trial was designed to test the value of postoperative radiation therapy in patients who presented with clinical T1-3N1 tumors with biopsy-proven axillary node involvement who had pathologically negative nodes (ypN0) on either sentinel node biopsy (SNB) or axillary lymph node dissection (ALND) after neoadjuvant chemotherapy (NACT). Of importance, the treatment ...
(more)
Simul Parikh
Lake Huron Medical Center
Micrometastases are not specifically associated with increased IBTR. I would use whatever algorithm you typically use to determine whether or not you boost.
(more)
Bruce Haffty
Rutgers Robert Wood Johnson Medical School
There are a number of studies, including the one below, that suggest that favorable ER/PR+, Her2 negative patients with T3N0 have low local recurrence rates without PMRT. Every case is individualized and should take into consideration all factors including size, margins, and other adverse features but in the case above, yes, I would consider eliminating PMRT.Floyd et al., PMID 16887288
(more)
I generally start radiation between 3 and 8 weeks following the last dose of chemotherapy. Since most protocol guidelines specify radiation should start within 12 weeks of the last day of chemo is within the last surgical procedure, I use that as an outside window I am comfortable with for the most part.
Currently in light of coronavirus I still use those guidelines and don’t delay beyond that, since it is unclear if things will be better or safer in the next couple of months. So I would not at this point delay a patient beyond approximately 12 weeks with some modest flexibility.